BioSpace News Archive

Syndax Pharmaceuticals, Inc. and Incyte announced that they have entered into an exclusive worldwide collaboration and license agreement to develop and commercialize axatilimab, Syndax’s anti-CSF-1R monoclonal antibody.

Synlogic, Inc., a clinical stage company bringing the transformative potential of synthetic biology to medicine, announced the appointment of Molly Harper as Chief Business Officer.

Pfizer Inc. announced the start of the Phase 2/3 EPIC-PEP study to evaluate the investigational novel oral antiviral candidate PF-07321332, co-administered with a low dose of ritonavir, for the prevention of COVID-19 infection.

Merck, known as MSD outside the United States and Canada, announced that the Phase 3 KEYNOTE-394 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in Asian patients with advanced hepatocellular carcinoma previously treated with sorafenib met its primary endpoint of overall survival.

Passage Bio, Inc., a genetic medicines company focused on developing transformative therapies for central nervous system disorders, announced that management will participate in two upcoming conferences in October.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), today announced it has entered into a definitive agreement with ten accredited investors in a private placement of $30 million of DiaMedica’s common shares at a purchase price of $3.92 per share, equal to the per share closing price of the Company’s common shares on September 24, 2021.

Aditxt, Inc. today announced key executive management changes to support its growth plans. Corinne Pankovcin, who has served as CFO of Aditxt, has been appointed as President and will work closely with the Company’s CEO, Amro Albanna, to execute Aditxt’s business strategy.

Denali Therapeutics Inc. today announced the appointment of Katie Peng to the newly created role of Chief Commercial Officer.

Pacific Biosciences of California, Inc. (Nasdaq: PACB)(“Pacific Biosciences” or “PacBio”), a leading provider of high-quality, highly accurate sequencing platforms, today announced a partnership with The European Reference Genome Atlas (ERGA) consortium to support its efforts in understanding and protecting biodiversity by generating high-quality reference genomes for European plant and animal species.

Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. a global specialty pharmaceutical company, welcomed Paula Soteropoulos, a biopharma industry veteran, as the newest non-executive Director on its North America Board of Directors, effective September 1, 2021.